• Je něco špatně v tomto záznamu ?

Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer

M. Abufaraj, SF. Shariat, A. Haitel, M. Moschini, B. Foerster, P. Chłosta, K. Gust, M. Babjuk, A. Briganti, PI. Karakiewicz, W. Albrecht,

. 2017 ; 35 (5) : 264-271. [pub] 20170214

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc18010793

PURPOSE: To assess the role of N-cadherin as a prognostic biomarker in patients with non-muscle-invasive bladder cancer (NMIBC) treated with transurethral resection with or without adjuvant intravesical therapy. PATIENTS AND METHODS: Immunohistochemistry using monoclonal mouse antibody was used to evaluate the expression status of N-cadherin in 827 patients with NMIBC. N-cadherin was considered positive if any immunoreactivity with membranous staining was detected. Multivariable Cox regression models were performed to evaluate the prognostic effect of N-cadherin on survival outcomes. RESULTS: N-cadherin expression was observed in 333 patients (40.3%); it was associated with pT1 stage and high tumor grade (both were P<0.001). Median follow-up was 55 months (interquartile range: 18-106). On multivariable Cox regression analyses that adjusted for the effect of the standard clinicopathologic features, N-cadherin expression remained associated with recurrence-free survival (P = 0.007) but not progression-free survival (P = 0.3), cancer-specific survival (P = 0.2), or overall survival (P = 0.9). Adding N-cadherin to a model for prediction of disease recurrence modestly improved its discrimination from 72.8% to 73.4%. CONCLUSION: N-cadherin is expressed in approximately 2/5 patients with NMIBC. Its expression is associated with adverse pathological features and higher risk of disease recurrence but not progression. N-cadherin could be incorporated in predictive tools to assist in recurrence prediction helping thereby in patient selection regarding adjuvant therapies and follow-up planning.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18010793
003      
CZ-PrNML
005      
20180420094811.0
007      
ta
008      
180404s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.urolonc.2017.01.012 $2 doi
035    __
$a (PubMed)28214283
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Abufaraj, Mohammad $u Department of Urology, Medical University of Vienna, Vienna, Austria.
245    10
$a Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer / $c M. Abufaraj, SF. Shariat, A. Haitel, M. Moschini, B. Foerster, P. Chłosta, K. Gust, M. Babjuk, A. Briganti, PI. Karakiewicz, W. Albrecht,
520    9_
$a PURPOSE: To assess the role of N-cadherin as a prognostic biomarker in patients with non-muscle-invasive bladder cancer (NMIBC) treated with transurethral resection with or without adjuvant intravesical therapy. PATIENTS AND METHODS: Immunohistochemistry using monoclonal mouse antibody was used to evaluate the expression status of N-cadherin in 827 patients with NMIBC. N-cadherin was considered positive if any immunoreactivity with membranous staining was detected. Multivariable Cox regression models were performed to evaluate the prognostic effect of N-cadherin on survival outcomes. RESULTS: N-cadherin expression was observed in 333 patients (40.3%); it was associated with pT1 stage and high tumor grade (both were P<0.001). Median follow-up was 55 months (interquartile range: 18-106). On multivariable Cox regression analyses that adjusted for the effect of the standard clinicopathologic features, N-cadherin expression remained associated with recurrence-free survival (P = 0.007) but not progression-free survival (P = 0.3), cancer-specific survival (P = 0.2), or overall survival (P = 0.9). Adding N-cadherin to a model for prediction of disease recurrence modestly improved its discrimination from 72.8% to 73.4%. CONCLUSION: N-cadherin is expressed in approximately 2/5 patients with NMIBC. Its expression is associated with adverse pathological features and higher risk of disease recurrence but not progression. N-cadherin could be incorporated in predictive tools to assist in recurrence prediction helping thereby in patient selection regarding adjuvant therapies and follow-up planning.
650    _2
$a senioři $7 D000368
650    _2
$a nádorové biomarkery $x metabolismus $7 D014408
650    _2
$a kadheriny $x metabolismus $7 D015820
650    _2
$a progrese nemoci $7 D018450
650    _2
$a přežití bez známek nemoci $7 D018572
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a stupeň nádoru $7 D060787
650    _2
$a invazivní růst nádoru $7 D009361
650    _2
$a lokální recidiva nádoru $x metabolismus $7 D009364
650    _2
$a staging nádorů $7 D009367
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a míra přežití $7 D015996
650    _2
$a nádory močového měchýře $x metabolismus $x patologie $x terapie $7 D001749
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Shariat, Shahrokh F $u Department of Urology, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, University of Texas Southwestern Medical Centre, Dallas, TX; Department of Urology, Weill Cornell Medical College, New York, NY.
700    1_
$a Haitel, Andrea $u Department of Pathology, Medical University of Vienna, Vienna, Austria.
700    1_
$a Moschini, Marco $u Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy.
700    1_
$a Foerster, Beat $u Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland.
700    1_
$a Chłosta, Piotr $u Department of Urology, Jagiellonian University, Krakow, Poland.
700    1_
$a Gust, Kilian $u Department of Urology, Medical University of Vienna, Vienna, Austria.
700    1_
$a Babjuk, Marek $u Department of Urology, Medical University of Vienna, Vienna, Austria; Department of Urology, Hospital Motol, Second Faculty of Medicine, Charles University, Praha, Czech Republic.
700    1_
$a Briganti, Alberto $u Department of Urology, Urological Research Institute, Vita-Salute University, San Raffaele Scientific Institute, Milan, Italy.
700    1_
$a Karakiewicz, Pierre I $u Department of Urology, University of Montreal, Montreal, Canada.
700    1_
$a Albrecht, Walter $u Department of Urology, Landesklinikum Mistelbach, Mistelbach, Austria. Electronic address: walter.albrecht@mistelbach.lknoe.at.
773    0_
$w MED00008671 $t Urologic oncology $x 1873-2496 $g Roč. 35, č. 5 (2017), s. 264-271
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28214283 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20180420094914 $b ABA008
999    __
$a ok $b bmc $g 1288278 $s 1007605
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 35 $c 5 $d 264-271 $e 20170214 $i 1873-2496 $m Urologic oncology $n Urol Oncol $x MED00008671
LZP    __
$a Pubmed-20180404

Najít záznam

Citační ukazatele

Možnosti archivace